ArticleEpilepsia2026
Long-term outcomes of stereotactic radiofrequency ablation in hypothalamic hamartomas: A single-center experience.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epilepsy: Molecular Pathogenesis and Emerging Therapies.MedComm · 2026Review
- Long-term outcomes of stereotactic radiofrequency ablation in hypothalamic hamartomas: A single-center experience.Epilepsia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHypothalamic hamartomas (HHs) lead to refractory epilepsy, and minimally invasive surgical approaches are standard of care for affected patients. Stereotactic radiofrequency thermocoagulation (SRT) is one of the treatment methods recognized to achieve seizure freedom. This study reports surgical outcome from a single center reporting an ablation technique using fewer trajectories than previously reported and assesses the effect of coagulated volume on long-term seizure freedom.
methodsRetrospective analysis was made of all patients who underwent SRT at the University of Freiburg between 2016 and 2024 with a follow-up of ≥12 months. Statistical analysis was made of outcome dependent on type of hamartoma, seizure type, coagulation volume (based on magnetic resonance imaging evaluation), and epilepsy duration.
resultsForty-three patients received SRT; 35 (22 children) had >12 months of follow-up, with a median of 38 months. Nine patients had two SRTs, and two patients had three SRTs. Twelve months after their last SRT, 60% of patients were seizure-free, 88.6% were free of bilateral tonic-clonic seizures, and 77.1% were free of gelastic seizures (last follow-up: 54.3% seizure-free, 88.6% free of bilateral tonic-clonic seizures, 74.3% free of gelastic seizures). There was a significant reduction of antiseizure medication (ASM) postsurgically, with an average number of ASMs of two prior to surgery and one after surgery. After 12 months, 14.3% of patients experienced ongoing but mostly mild surgical complications, with hypothalamic dysfunction being the most common. Coagulation volumes were higher in larger HHs, but no correlation was observed between coagulated volume and seizure freedom or complication rates. SIGNIFICANCE: SRT is a minimally invasive method to successfully treat refractory seizures in patients with HH. Disconnection seems to be more important for successful treatment than volume reduction. Even large HHs can be successfully treated with small coagulation volumes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.